Weight loss drugs have been touted as a game-changer for millions of Americans struggling with obesity. However, new research from the Cleveland Clinic suggests that these medications may not deliver the promised results when used in real-life settings.
Researchers studied nearly 7,900 adults who took weight loss shots between 2021 and 2023, including those with pre-diabetes. The study found that patients who discontinued treatment early or used lower dosages lost significantly less weight compared to those who continued treatment with higher dosages.
On average, participants who stopped taking the medication after just three months lost 3.6% of their body weight, while those who stopped later lost an average of 6.8%. In contrast, those who maintained high doses and stayed on the medication for a year lost up to 13.7% and 18%, respectively.
The study’s findings have implications for people considering using these medications, which are taken by over eight million Americans every year. The Cleveland Clinic researchers noted that patients with pre-diabetes were at higher risk of developing type 2 diabetes and needed effective blood sugar control.
While the weight loss results may be disappointing, the study suggests that maintaining a high dose of medication can still lead to significant weight reductions. However, more research is needed to understand the long-term effects of treatment discontinuation on patients’ weight trajectories.
The Cleveland Clinic researchers emphasize that their findings could inform healthcare providers and patients about the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions.
Source: https://www.independent.co.uk/news/health/weight-loss-drugs-diabetes-b2767346.html